DMLA exsudative: cas cliniques

Salomon-Yves Cohen

Centre d'Imagerie et de Laser, Paris


10/12/2008
Couleur (comp.


10/12/2008
FLUO
00:00:21


10/12/2008
FLUO
00:01:57



AV = 20/32

3 IVT Lucentis


06/04/2009
Couleur (comp.




20/05/2009
Couleur (comp.






09/09/2009
Couleur (comp.





AV = 20/25 (83 lettres)

Toujours sec en OCT

Toujours sec en OCT

Poursuivre les contrôles mensuels ?

A vie ??

Quid des néovaisseaux juxta et extra-fovéolaires ?







Photocoagulation des NVV

Indications résiduelles ?

A partir de quelle distance / fovéola ?

La dimension du néovaisseau intervient-elle dans la décision ?

Sa topographie intervient-elle ?


28/06/2007
Couleur (comp.


28/06/2007
VERT


28/06/2007
FLUO
00:00:26



AV = 20/40, 4 IVT de Lucentis


13/12/2007
Couleur (comp.





AV = 20/32, surveillance mensuelle


07/01/2008
Couleur (comp.





Récidive 15 jours après un contrôle satisfaisant,
accueil en urgence: plusieurs IVT en 2008


17/12/2008
Couleur (comp.





Evolution cyclique: 8 IVT OD


09/09/2009
Couleur (comp.





AV = 20/40, Sec en OCT après 13 IVT OD

Poursuivre ou anticiper les récidives ?


12/03/2007
Couleur (comp.


12/03/2007
FLUO
00:00:15


12/03/2007
FLUO
00:03:03





AV = 20/64, BAV ressentie, 1 IVT Lucentis


02/05/2007
Couleur (comp.


02/05/2007
FLUO
00:00:28


02/05/2007
FLUO
00:03:15





30/07/2007





Couleur (comp.




10/12/2007






22/04/2008
Couleur (comp.


09/09/2009

Evolution cyclique

Tendance à la fibrose

AV = 20/80 après 9 IVT

Continuer ?

Peut-on faire mieux ?

Schéma thérapeutique
Dr Sam Razavi (Tours)









Persistance ACR après 4 IVT Lucentis





J10 POST Triam + Lucentis >>> PDT





M3 post ttt Triple





M6 post ttt Triple


21/02/2007
Couleur (comp.


21/02/2007
FLUO
00:00:24


21/02/2007
FLUO
00:02:46





3 IVT, puis espacement progressif des contrôles et des IVT


10/09/2009
Couleur (comp.





Acuité 20/100 meilleur œil, 12 IVT, 1 IVT tous les 3 mois

Retraitements systématiques / 3 mois ?









Gêne modérée, AV = 20/20 (85 lettres)

Décision de surveillance











Petite modification fonctionnelle: 20/20 (82 lettres)

Angio: NVO, Pas d'exsudation significative à l'OCT